Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma-Reference-Cited by-同舟云学术

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Published:2024-07-18 Issue:3 Volume:144 Page:334-338
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Crochet Gilles¹,Iacoboni Gloria²³^ORCID,Couturier Audrey⁴^ORCID,Bachy Emmanuel⁵^ORCID,Iraola-Truchuelo Josu³^ORCID,Gastinne Thomas⁶,Cartron Guillaume⁷^ORCID,Fradon Tom⁸,Lesne Bastien⁸,Kwon Mi⁹^ORCID,Gounot Romain¹⁰,Martínez-Cibrian Nuria¹¹,Castilla-Llorente Cristina¹²,Abrisqueta Pau²³,Guerreiro Manuel¹³^ORCID,Sarkozy Clémentine¹⁴,Aspa-Cilleruelo Jose María¹⁵^ORCID,Camus Vincent¹⁶,Guidez Stéphanie¹⁷,Chauchet Adrien¹⁸,Deconinck Eric¹⁸^ORCID,Bouabdallah Krimo¹⁹,Bosch Francesc²³,Barba Pere²³^ORCID,Morschhauser Franck²⁰^ORCID,Houot Roch⁴^ORCID

Affiliation:

1. 1Centre Hospitalier Universitaire UCLouvain Namur, Yvoir, Belgium

2. 2Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

3. 3Vall d’Hebron Institute of Oncology, Barcelona, Spain

4. 4Centre Hospitalier Universitaire de Rennes, Rennes, France

5. 5Hospices Civils de Lyon, Pierre-Bénite, France

6. 6Nantes University Hospital, Nantes, France

7. 7Centre Hospitalier Universitaire Montpellier, Montpellier, France

8. 8LYSARC, The Lymphoma Academic Research Organization, Pierre-Bénite, France

9. 9Hospital General Universitario Gregorio Marañón, Madrid, Spain

10. 10Hôpital Henri Mondor, Créteil, France

11. 11Hospital Clínic, Barcelona, Spain

12. 12Institut de Cancérologie Gustave Roussy, Villejuif, France

13. 13Hospital Universitari I Politècnic La Fe, Valencia, Spain

14. 14Institut Gustave Roussy, Villejuif, France

15. 15Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Madrid, Spain

16. 16Centre Henri Becquerel, Rouen, France

17. 17Centre Hospitalier Universitaire Poitiers, Poitiers, France

18. 18Centre Hospitalier Universitaire Besançon, Besançon, France

19. 19Centre Hospitalier Universitaire Haut-Leveque, Pessac, France

20. 20Centre Hospitalier Universitaire Lille, Lille, France

Abstract

Abstract In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.

Publisher

American Society of Hematology

Link

https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2024024526/2234575/blood_bld-2024-024526-main.pdf

Reference22 articles.

1. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma;Dickinson;N Engl J Med,2022

2. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial;Thieblemont;J Clin Oncol,2023

3. Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial;Bannerji;Lancet Haematol,2022

4. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study;Budde;J Clin Oncol,2022

5. A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin’s lymphoma: recommended dose safety/efficacy update and escalation exposure-response analysis [abstract];Patel;Blood,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

2. Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data;International Journal of Molecular Sciences;2024-09-09

3. Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration;Cancer Medicine;2024-09

4. Boosting CAR T cells against lymphomas;Blood;2024-08-15

5. CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models;Blood;2024-08-15